CUSIP: G5269C101
Q3 2018 13F Holders as of 30 Sep 2018
-
Type / Class
-
Equity / COM
-
Total 13F shares
-
14,420,950
-
Share change
-
-3,169,264
-
Total reported value
-
$363,005,519
-
Price per share
-
$25.50
-
Number of holders
-
54
-
Value change
-
-$79,063,573
-
Number of buys
-
35
-
Number of sells
-
24
Quarterly Holders Quick Answers
What is CUSIP G5269C101?
CUSIP G5269C101 identifies KNSA - Kiniksa Pharmaceuticals Intern - COM in SEC institutional holdings data.
Need full ownership history?
Open the full security ownership history page.
Explore More Reporting Periods
Jump to adjacent filing periods for faster comparison and easier crawl discovery.
-
Newer quarter:
Q4 2018
-
Previous quarter:
Q2 2018
Recent filing periods for CUSIP G5269C101:
Institutional Holders of Kiniksa Pharmaceuticals Intern - COM (KNSA) as of Q3 2018
As of 30 Sep 2018,
Kiniksa Pharmaceuticals Intern - COM (KNSA) was held by
54 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
14,420,950 shares.
The largest 10 holders included
BAKER BROS. ADVISORS LP, Hillhouse Capital Management, Ltd., ArrowMark Colorado Holdings LLC, BOXER CAPITAL, LLC, DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C), Sofinnova Ventures Inc, Cormorant Asset Management, LP, FMR LLC, VHCP Management II, LLC, and Vanguard Group Inc.
This page lists
54
institutional shareholders reporting positions in this security
for the Q3 2018 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.